Background: Abiraterone acetate combined with Prednisone/Prednisolone (AA+P) and Enzalutamide (ENZ) have proven survival benefit in men with metastatic castration-resistant prostate cancer (mCRPC) in chemotherapy-naïve and prior chemotherapy patients. There have been no studies directly comparing the effectiveness of ENZ to AA+P in mCRPC patients.
Methods: A retrospective, survival analysis study of 143 real-world mCRPC patients (90 in AA+P and 53 in ENZ group) was conducted. Patients who started their treatment between February 2012 and May 2016 were included. The primary end point was biochemical progression-free survival (bPFS). Secondary end points were radiological progression-free survival (rPFS) and overall survival (OS). Toxicity data were also collected. Data were analyzed using Cox proportional hazards (PH) models, adjusting for covariates: prior radical treatment; Gleason score; prostate-specific antigen; age; and chemotherapy naïve or not.
Results: After median follow-up of 15 months (interquartile range 7 to 23), 112 events of biochemical progression were observed (71 in AA+P and 41 in ENZ). About 41% in AA+P group and 30% patients in ENZ group received prior chemotherapy. The chance of biochemical progression was significantly lower among ENZ patients than AA+P patients, when adjusting for all covariates in the Cox PH model (hazard ratio [HR] 0.54, 95% confidence interval [CI] 0.35 to 0.82, = .004). There was a trend implying the chance of rPFS could be higher among ENZ patients than AA+P patients (HR 1.24, 95% CI 0.76 to 2.02, = .4). There is no difference in OS between ENZ and AA+P patients, when adjusting for all covariates in the Cox PH model (HR 0.91, 95% CI 0.59 to 1.41, = .7). About 38% of ENZ patients reported fatigue compared to 16% of AA+P patients, while hypertension was reported slightly more in AA+P patients.
Conclusions: This study showed a statistically significant difference in bPFS, favoring ENZ, but no significant difference in rPFS or OS.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8988641 | PMC |
| http://dx.doi.org/10.1002/bco2.11 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Non-smoking and Non-drinking Oral Cancer Patients Are at Higher Risk of Second Primary Tumours.
Oral Dis
December 2024
Department of Oral and Maxillofacial Surgery, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Objectives: This study aimed to explore differences in demographics, tumour characteristics and outcomes in oral squamous cell carcinoma (OSCC) patients with a history of non-smoking, non-drinking (NSND) versus smoking and/or drinking (SD).
Materials And Methods: Newly diagnosed OSCC patients undergoing curative surgical treatment were prospectively included in OncoLifeS, a data biobank. Cox regression analysis was performed yielding hazard ratios (HRs) and 95% confidence intervals (95%CIs).
Intradermal skin testing in the investigation of suspected anaphylactic reactions during anaesthesia--a retrospective survey.
Acta Anaesthesiol Belg
July 2003
Department of Anesthesie en Reanimatie, Sint-Elisabeth Hospital, Rubensstraat 166, 2300 Turnhout, Belgium.
An anaphylactic reaction is a rare, but severe anaesthetic complication. In this retrospective survey we report on patients with a severe suspected anaphylactic reaction during anaesthesia and the investigation with intradermal skin testing of these suspected anaphylactic reactions. In the patients with an anaphylactic reaction to neuromuscular blocking drugs, the subsequent anaesthetic history was examined.
View Article and Find Full Text PDFCarboxyhemoglobin concentrations during desflurane and isoflurane closed-circuit anesthesia.
Acta Anaesthesiol Belg
November 1996
Department of Anesthesiology and Critical Care Medicine, University of Pittsburgh School of Medicine, Pennsylvania, USA.
Desflurane has been implicated in carbon monoxide (CO) intoxication during general anesthesia under certain circumstances. Carboxyhemoglobin (COHb) concentrations were determined in forty-one patients who were randomly allocated to receive closed-circuit anesthesia (CCA) with 1.3 MAC of desflurane (n = 21) or isoflurane (n = 20) in oxygen.
View Article and Find Full Text PDFCentral venous plasma concentrations of bupivacaine were determined in two groups of 15 parturients each who were given epidural analgesia for labor and vaginal delivery. One group received 10 ml of 0.125% bupivacaine plus epinephrine 1:800,000, the other group received 7 ml of 0.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!